BPS-Pharmacotherapy Exam Dumps | A study shows that the participants who received 6 months of a new oral anticoagulant after a venous

<< Prev Question Next Question >>

Question 8/60

A study shows that the participants who received 6 months of a new oral anticoagulant after a venous thromboembolism were randomized to continue with the new oral anticoagulant (n =
612) or to placebo (n = 611) for 18 months. Thromboembolism recurred in 12 subjects in the new oral anticoagulant group and 71 subjects in the placebo group (hazard ratio 0.17; 95% CI, 0.09-
0.30; p < 0.001).
Which of the following statements regarding these results is correct?

A. The difference between the new oral anticoagulant and placebo in the secondary prevention of venous thromboembolism is not statistically significant.

B. The new oral anticoagulant reduces the relative risk of a secondary venous thromboembolism by 83% compared to placebo.

C. The new oral anticoagulant reduces the relative risk of a secondary venous thromboembolism by 17% compared to placebo.

D. The new oral anticoagulant reduces the relative risk of a secondary venous thromboembolism by 9.6% compared to placebo.

Question 8/60

LEAVE A REPLY

Download PDF File